Trevena Inc. (NASDAQ:TRVN) has earned an average recommendation of “Buy” from the eleven ratings firms that are currently covering the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $14.75.

A number of brokerages have commented on TRVN. Cowen and Company restated a “buy” rating and set a $13.00 price target on shares of Trevena in a research note on Friday, August 5th. FBR & Co restated a “buy” rating and set a $13.00 price target on shares of Trevena in a research note on Thursday, August 4th. Wedbush restated an “outperform” rating and set a $16.00 price target on shares of Trevena in a research note on Thursday, November 3rd. Brean Capital restated a “buy” rating and set a $14.00 price target on shares of Trevena in a research note on Friday, August 5th. Finally, Zacks Investment Research upgraded shares of Trevena from a “sell” rating to a “hold” rating in a research note on Wednesday, July 20th.

In related news, CEO Maxine Gowen acquired 12,500 shares of the company’s stock in a transaction that occurred on Monday, November 7th. The stock was purchased at an average price of $4.10 per share, for a total transaction of $51,250.00. Following the transaction, the chief executive officer now directly owns 16,500 shares of the company’s stock, valued at approximately $67,650. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.40% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN raised its stake in Trevena by 51.9% in the third quarter. Wells Fargo & Company MN now owns 15,393 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 5,261 shares in the last quarter. National Planning Corp raised its stake in Trevena by 21.9% in the first quarter. National Planning Corp now owns 19,452 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 3,500 shares in the last quarter. Alliancebernstein L.P. acquired a new stake in Trevena during the second quarter worth approximately $163,000. Highbridge Capital Management LLC acquired a new stake in Trevena during the second quarter worth approximately $225,000. Finally, Metropolitan Life Insurance Co. NY raised its stake in Trevena by 54.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 35,964 shares of the biopharmaceutical company’s stock worth $227,000 after buying an additional 12,694 shares in the last quarter. 75.17% of the stock is owned by hedge funds and other institutional investors.

Trevena (NASDAQ:TRVN) opened at 6.09 on Thursday. Trevena has a 52 week low of $3.76 and a 52 week high of $13.02. The company’s market capitalization is $318.71 million. The firm’s 50-day moving average price is $5.80 and its 200-day moving average price is $6.65.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by $0.17. Trevena had a negative return on equity of 66.50% and a negative net margin of 841.00%. On average, equities analysts expect that Trevena will post ($1.91) earnings per share for the current year.

Trevena Company Profile

Trevena Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.

5 Day Chart for NASDAQ:TRVN

Receive News & Stock Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related stocks with our FREE daily email newsletter.